Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
In this retrospective analysis, HER2 expression is common in breast cancer BrMs, emphasizing the need for improved, noninvasive diagnostics. Patients with HER2-low and HER2-0 BrMs face inferior survival, presenting an unmet clinical need.
Authors
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
- Janet Files
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- Alyssa Pereslete (ORCID: https://orcid.org/0000-0001-7995-7507)
- Deborah Dillon (ORCID: https://orcid.org/0000-0002-4977-6673)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Abigail Moore (ORCID: https://orcid.org/0000-0001-9546-2942)
- Lauren Buckley
- Ashka Patel
- Tianyu Li (ORCID: https://orcid.org/0000-0003-2706-2685)
- Kyleen Nguyen
- Alyssa R. Martin
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Florida International University (US)
- Yale Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1093/neuonc/noae163
- Citations
- 11
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- Alpha Omega Alpha Honor Medical Society